Canaccord Genuity Starts Neoleukin Therapeutics (NLTX) at Buy
Tweet
Share
E-mailGet Alerts NLTX Hot Sheet
Price: $3.49 --0%
Rating Summary:
2 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity analyst Arlinda Lee initiates coverage on Neoleukin Therapeutics (NASDAQ: NLTX) with a Buy rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Neoleukin Therapeutics click here. For more ratings news on Neoleukin Therapeutics click here.
Shares of Neoleukin Therapeutics closed at $7.96 yesterday.
You May Also Be Interested In
- Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
- BMO Capital Starts Energy Fuels (UUUU) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
